Miltefosine is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please sign in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Miltefosine is available under an expanded access IND form the CDC (770-488-7100) in the U.S. for the treatment of free-living ameba, including primary meningoencephalitis (PAM) caused by Naegleria fowleri and granulomatous amebic encephalitis (GAM) caused by Balamuthia mandrillaris and Acanthamoeba species.
- Treatment of cutaneous, mucosal, and visceral leishmaniasis in patients >12 years of age.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Use in combination with voriconazole and terbinafine for the management of Scedosporium prolificans
-- To view the remaining sections of this topic, please sign in or purchase a subscription --
Last updated: April 5, 2016
Citation
* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Miltefosine
ID - 540350
A1 - Dzintars,Kathryn,Pharm.D., BCPS
AU - Pham,Paul,Pharm.D.
Y1 - 2016/04/05/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540350/all/Miltefosine
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -